Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 801–900 of 1,000
Telomere Maintenance in Pediatric Cancer
Ackermann, S., & Fischer, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235836 · Cited by 16
“ALT was originally discovered in immortalized cell lines and subsequently shown to occur in human tumors [141,142].”
BackgroundMethodYamamoto, Y., Yamamoto, N., Tajima, K., Ohno, A., Washimi, Y., Ishimura, D., Washimi, O., & Yamada, H. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0885-9 · Cited by 15
“Most cancer cells activate the enzyme telomerase to maintain their telomeres, whereas some osteosarcoma cells (Scheel et al. 2001; Ulaner et al. 2003) use an incompletely defined recombination-based mechanism called alternative lengthening of telomeres (ALT) (Kim et al. 1994; Shay and Bacchetti 1997; Bryan et al. 1997…”
BackgroundMaláska, J., Skleničková, M., Krejčı́, K., Fajkusová, L., Bajer, M., Hrstková, H., & Fajkus, J. (2000) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0332 · Cited by 15
Telomerase inhibition and telomere erosion: a two-pronged strategy in cancer therapy
Odago, F., & Gerson, S. L. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00165-2 · Cited by 15
Finnon, P., Wong, H.-P., Silver, A. R., Slijepčević, P., & Bouffler, S. D. (2001) · International Journal of Radiation Biology · doi:10.1080/09553000110075220 · Cited by 16
“The ladder of TRAP products to maintain telomere length in the absence of telowas absent in heat-treated extracts of 7926 and merase in immortal cell lines (Bryan et al. 1997a, TRAP activities exhibited a similar responses to both Colgin and Reddel 1999) .”
BackgroundKojima, H., Yokosuka, O., Kato, N., Shiina, S., Imazeki, F., Saisho, H., Shiratori, Y., & Omata, M. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80045-2 · Cited by 15
The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients
Muyas, F., Gómez, M. J., Cascão, R., Afonso, Â., Sauer, C. M., Faria, C. C., Cortés‐Ciriano, I., & Flores, I. (2024) · Nature Communications · doi:10.1038/s41467-023-44287-8 · Cited by 17
Córdoba-Lanús, E., Montuenga, L. M., Domínguez-de-Barros, A., Oliva, A., Mayato, D., Remírez-Sanz, A., Gonzalvo, F., Celli, B. R., Zulueta, J. J., & Casanova, C. (2024) · Antioxidants · doi:10.3390/antiox13020156 · Cited by 15
“In addition to this, there is another mechanism for telomere elongation, known as “alternative telomere lengthening” or ALT, which has been documented in 10–15% of cancers [41].”
BackgroundOrphan nuclear receptors-induced ALT-associated PML bodies are targets for ALT inhibition
Gaela, V. M., Hsia, H.-Y., Joseph, N. A., Tzeng, W.-Y., Ting, P.-C., Shen, Y., Tsai, C.-T., Boudier, T., & Chen, L. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae389 · Cited by 16
“The ALT pathway is a homologous recombination-based telomere maintenance mechanism relying on break-induced replication (BIR)-mediated ALT telomere DNA synthesis ( 5–7 ).”
BackgroundKim, S., Park, S. H., Kang, N., Ra, J. S., Myung, K., & Lee, K. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae785 · Cited by 15
“Furthermore, 10–15% of human cancers adopt a recombination-dependent alternative lengthening of telomeres (ALT) pathway instead of TEL activity ( 4 ,5 ).”
BackgroundTumour virology – history, status and future challenges
Kalland, K.-H., Ke, X., & Oyan, A. M. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02452.x · Cited by 18
“In the remaining 10% of cancers an alternative lengthening of telomeres pathway (ALT) has been activated (114).”
BackgroundNovo, C. L., & Londoño‐Vallejo, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.001 · Cited by 16
The Role of Ubiquitination and SUMOylation in Telomere Biology
Zalzman, M., Meltzer, W. A., Portney, B. A., Brown, R. A., & Gupta, A. (2019) · Current Issues in Molecular Biology · doi:10.21775/cimb.035.085 · Cited by 18
“The remaining telomerase negative cancers must activate other mechanisms to maintain telomere integrity which are collectively called: Alternative Lengthening of Telomeres (ALT) mechanisms (Bryan et al., 1997; Cesare and Reddel, 2010).”
BackgroundA critical role of telomere chromatin compaction in ALT tumor cell growth
Shi, G. W., Hu, Y., Zhu, X. Q., Jiang, Y., Pang, J., Wang, C., Huang, W., Zhao, Y. B., Ma, W., Liu, D., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa224 · Cited by 17
“Telomerasenegative cancer cells maintain telomeres through the alternative lengthening of telomeres (ALT) pathway that depends on homologous recombination (HR) (1).”
BackgroundAd Astra – telomeres in space!
Bailey, S. M., Luxton, J. J., McKenna, M. J., Taylor, L. E., George, K. A., Jhavar, S. G., & Swanson, G. P. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1956010 · Cited by 16
“The remaining 10 to15% of cancers maintain telomere length via the telomerase independent, recombination-based Alternative Lengthening of Telomeres (ALT) pathway of telomere maintenance (Murnane et al. 1994; Bryan et al. 1997; Dunham et al. 2000).”
BackgroundDynamic Activity of Histone H3-Specific Chaperone Complexes in Oncogenesis
Wen, T., & Chen, Q. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.806974 · Cited by 14
Hübner, B., von Otter, E., Ahsan, B., Wee, M. L., Henriksson, S., Ludwig, A., & Sandin, S. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac309 · Cited by 15
“Compared to telomerase-positive MEFs (39) and HT1080 cells (40), telomeres of U2OS ALT cells (41) were clearly less compact.”
A Comprehensive Review on the Role of ZSCAN4 in Embryonic Development, Stem Cells, and Cancer
Thool, M., Sundaravadivelu, P. K., Selvaraju, S., & Thummer, R. P. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10412-1 · Cited by 17
“Alternative lengthening of telomeres (ALTs) is an alternative mechanism for telomere elongation, which is independent of telomerase [69] and depends solely on homologous recombination [70].”
BackgroundSpangler, E. A., Rogers, K. S., Thomas, J. S., Pustejovsky, D., Boyd, S. L., & Shippen, D. E. (2000) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2000.tb02228.x · Cited by 14
Multiscalein situanalysis of the role of dyskerin in lung cancer cells
Fernandez‐Garcia, I., Marcos, T. K., Muñoz‐Barrutia, A., Serrano, D., Pío, R., Montuenga, L. M., & Ortíz-de-Solórzano, C. (2012) · Integrative Biology · doi:10.1039/c2ib20219k · Cited by 14
Tumor viruses and replicative immortality – Avoiding the telomere hurdle
Chen, X., Kamranvar, S. A., & Masucci, M. G. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.01.006 · Cited by 17
The Epigenetic Regulation of Telomere Maintenance in Aging
Shekhidem, H. A., & Atzmon, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811060-7.00005-x · Cited by 16
TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes
Armendáriz‐Castillo, I., López‐Cortés, A., García-Cárdenas, J. M., Guevara‐Ramírez, P., Leone, P., Pérez‐Villa, A., Yumiceba, V., Zambrano, A. K., Guerrero, S. X., & Paz‐y‐Miño, C. (2020) · Genes · doi:10.3390/genes11070834 · Cited by 15
Lee, W. ‐. (2005) · Cytopathology · doi:10.1111/j.1365-2303.2005.00259.x · Cited by 14
Samassékou, O., Malina, A., Hébert, J., & Yan, J. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-26 · Cited by 14
“ALT occurs in about 10% of human tumors [2] and uses homologous recombination (HR) mediated replication to specifically elongate telomeres, which often results in different sizes of telomeres [3].”
Biological and clinical implications of telomere dysfunction in myeloid malignancies
Kishtagari, A., & Watts, J. M. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717731549 · Cited by 15
“A small subset of cancer cells extends their telomeres by the alternative lengthening of telomeres (ALT) pathway, which utilizes HR [Bryan et al. 1997].”
BackgroundBornstein-Quevedo, L., García-Hernández, M. D. L. L., Camacho‐Arroyo, I., Herrera, M. F., Ángeles, A., González-Treviño, O., & Gamboa‐Domínguez, A. (2003) · Endocrine Pathology · doi:10.1007/s12022-003-0013-3 · Cited by 14
“The existence of this phenomenon is supported by the presence of extremely long telomeres in telomerasenegative samples [ 24 ].”
BackgroundHerbert, B., Pearce, V., Hynan, L. S., LaRue, D. M., Wright, W. E., Kopelovich, L., & Shay, J. W. (2003) · PubMed · Cited by 21
Alzoubi, H., Minasi, S., Gianno, F., Antonelli, M., Belardinilli, F., Giangaspero, F., Jaffrain‐Rea, M., & Buttarelli, F. R. (2022) · Endocrine Pathology · doi:10.1007/s12022-021-09702-0 · Cited by 14
Azeroglu, B., Ozbun, L. L., Pegoraro, G., & Denchi, E. L. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.10.010 · Cited by 15
Telomere Reprogramming and Cellular Metabolism: Is There a Link?
Rubtsova, M. P., Никишин, Д. А., Vyssokikh, M. Y., Koriagina, M. S., Vasiliev, A. V., & Dontsova, O. А. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910500 · Cited by 15
“Telomeres may be elongated by telomerase [18] or through an alternative mechanism based on homologous recombination [19].”
BackgroundTRF1 and TRF2 form distinct shelterin subcomplexes at telomeres
Janovič, T., Perez, G. I., Boelting, G., & Schmidt, J. C. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116178 · Cited by 17
“8,9 How the shelterin complex carries out these distinct functions, balancing the recruitment of telomerase or proteins involved in ALT, with restriction of access for DNA damage repair proteins remains a critical unaddressed question in the field.”
Xu, N., Chen, Y., Dean, K. C., Lu, X., Liu, X., Wang, W., Dean, D. C., Kaplan, H. J., Gao, L., Dong, F., et al. (2017) · Stem Cells · doi:10.1002/stem.2585 · Cited by 13
TERT Alterations in Progressive Treatment-Resistant Meningiomas
Juratli, T. A., Brastianos, P. K., & Cahill, D. P. (2018) · Neurosurgery · doi:10.1093/neuros/nyy154 · Cited by 14
Nuclear envelope tethering inhibits the formation of ALT-associated PML bodies in ALT cells
Yang, C.-W., Hsieh, M., Sun, H.-J., & Teng, S. (2021) · Aging · doi:10.18632/aging.202810 · Cited by 13
Komosa, M., Root, H., & Meyn, M. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv091 · Cited by 13
“U2OS osteosarcoma ALT cells (30) also display significantly more ECTR DNA molecules per nucleus compared to primary and telomerase-positive cells (Figure 3A and B).”
BackgroundHofer, P., Zöchmeister, C., Behm, C., Brezina, S., Baierl, A., Doriguzzi, A., Vanas, V., Holzmann, K., Sutterlüty, H., & Gsur, A. (2017) · Oncotarget · doi:10.18632/oncotarget.15884 · Cited by 13
“However, a considerable number of cancers counteracts telomere attrition via alternative lengthening of telomeres [3, 4], a mechanism based on homologous recombination of telomeres (recently reviewed [5]).”
BackgroundSenescence and its bypass in the vascular endothelium
Deborah, A. F. (2005) · Frontiers in bioscience · doi:10.2741/1588 · Cited by 16
“In addition to containing ALT-stabilized telomeres, immortalized HUVEC expressing vGPCR produced ten-fold higher levels of vascular endothelial growth factor (VEGF) than control cells and maintained VEGF receptor 2 (VEGFR2) expression (for review of VEGF signaling see (59)).”
BackgroundInfluentialAlternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R
Fujiwara, M., Kamma, H., Wu, W., Yano, Y., Homma, S., & Satoh, H. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.2.445 · Cited by 13
Telomerase: a crucial player in HTLV-I-induced human T-cell leukemia.
Bellon, M., & Nicot, C. (2007) · PubMed · Cited by 19
Molecular Oncology of Breast Cancer
Ioan, A.-M., Klobocista, M. M., Shirazi, S., & Press, M. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00028-0 · Cited by 13
Polychronopoulou, S., & Koutroumba, P. (2004) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200406000-00003 · Cited by 14
“In respect to human species, long telomeres have been found in cancer cell lines lacking detectable TA, indicating that constant telomere lengthening in these cells is probably achieved through alternative mechanisms such as DNA recombination.(36) Focusing on the role of telomerase on cellular viability and immortaliz…”
BackgroundCapacitative calcium entry channels
Putney, J. W., & McKay, R. R. (1999) · BioEssays · doi:10.1002/(sici)1521-1878(199901)21:1<38::aid-bies5>3.0.co;2-s · Cited by 375
Rat, A., Martinez-Fernandez, V., Doumic, M., Teixeira, M. T., & Xu, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-56196-z · Cited by 15
“as fi rst described in budding yeast 5 – 7 .”
Clinical Use of ZSCAN4 for Telomere Elongation in Hematopoietic Stem Cells
Myers, K. C., Davies, S. M., Lutzko, C., Wahle, R., Grier, D. D., Aubert, G., Norris, K., Baird, D. M., Koga, M., Ko, A. C., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2400252 · Cited by 13
Mechanisms of fetal epigenetics that determine telomere dynamics and health span in adulthood
Ravlić, S., Vidaček, N. Š., Nanić, L., Laganović, M., Slade, N., Jelaković, B., & Rubelj, I. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.014 · Cited by 14
“telomeres) which is based on homologous recombination (Bryan et al., 1997; Henson et al., 2002).”
Maccaroni, K., Torre, M. L., Burla, R., & Saggio, I. (2022) · Cells · doi:10.3390/cells11111749 · Cited by 12
“Telomeres undergoing ALT are clustered to form the so-called ALT-associated PML bodies (APBs) [59,60].”
BackgroundKuzyk, A. C., & Mai, S. (2012) · Neoplasia · doi:10.1593/neo.12446 · Cited by 13
Techniques in Plant Telomere Biology
Fajkus, J., Sýkorová, E., & Leitch, A. R. (2005) · BioTechniques · doi:10.2144/05382rv01 · Cited by 13
Swc4 positively regulates telomere length independently of its roles in NuA4 and SWR1 complexes
Liu, J., Li, Q., He, M.-H., Hu, C., Dai, P., Meng, F., Zhou, B. O., & Zhou, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1150 · Cited by 12
Yazawa, M., Okuda, M., Uyama, R., Nakagawa, T., Kanaya, N., Nishimura, R., Sasaki, N., Masuda, K., Ohno, K., & Tsujimoto, H. (2003) · Journal of Veterinary Medical Science · doi:10.1292/jvms.65.573 · Cited by 12
“This cell line may have a telomerase-independent mechanism for maintaining telomere length, as shown in human cell lines immortalized in vitro and tumor-derived cell lines [5].”
BackgroundTélomère et cancer : quoi de plus à la fin ?
Brunori, M., & Gilson, É. (2005) · médecine/sciences · doi:10.1051/medsci/200521137 · Cited by 18
“APB (ALT-associated promyelocytic leukemia [PML] body).”
BackgroundInfluentialSun, H., Hong, M., Yang, Q., Li, C., Zhang, G., Yue, Q., Ma, Y., Li, X., & Li, C.-Z. (2019) · The Analyst · doi:10.1039/c9an00204a · Cited by 12
Telomere dysfunction and telomerase activation in cancer – a pathological paradox?
Calcagnile, O., & Gisselsson, D. (2007) · Cytogenetic and Genome Research · doi:10.1159/000108310 · Cited by 15
“It is important to note that some tumours lacking detectable telomerase activity maintain telomeres through a telomerase-independent route (Bryan et al., 1997), referred to as alternative lengthening of telomeres (ALT).”
BackgroundTelomerase, P53 and PCNA activity in osteosarcoma
Nakashima, H., Nishida, Y., Sugiura, H., Katagiri, H., Yonekawa, M., Yamada, Y. M. A., Iwata, H., Nagasaka, T., & Ishiguro, N. (2003) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(03)00117-3 · Cited by 12
An alternative lifestyle for immortalized oral keratinocytes
Reddel, R. R. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13818 · Cited by 12
“ALT and telomerase can coexist in the same cells in culture (18), and in tumors (20).”
Self-citationSoldateschi, D., Bravaccini, S., Berti, B., Brogi, A., Benicchi, T., Soldatini, C., Medri, L., Fabbri, F., Paola, F. D., Amadori, D., et al. (2005) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.05.019 · Cited by 12
Telomere Shortening by Cisplatin in Yeast Nucleotide Excision Repair Mutant
Ishii, K., Yang, W.-L., Cvijic, M. E., Kikuchi, Y., Nagata, I., & Chin, K. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4777 · Cited by 13
Chen, J. J. ‐., & Podlevsky, J. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10042-2 · Cited by 14
ALV Integration-Associated Hypomethylation at the TERT Promoter Locus
Lam, G., & BEEMON, K. L. (2018) · Viruses · doi:10.3390/v10020074 · Cited by 11
“Similar phenotypes can be achieved through a telomerase-independent process, known as alternative lengthening of telomeres (ALT), which has been observed in both humans [12,13] and chickens [14].”
BackgroundSun, H., Chen, G., Guo, B., Lv, S., & Yuan, G. (2023) · Journal of Cancer · doi:10.7150/jca.80097 · Cited by 12
“Surprisingly, we were unable to identify ALT characteristics in two other NSCLC cell lines, SK-LU-1 and hTERT mRNA-negative TA and hTERT [67, 68].”
BackgroundWang, Y., Zhu, W. J., Jang, Y., Sommers, J. A., Gong, Y., Puligilla, C., Croteau, D. L., Yang, Y., Kai, M., & Liu, Y. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad967 · Cited by 13
Polvani, S., Calamante, M., Foresta, V., Ceni, E., Mordini, A., Quattrone, A., D’Amico, M., Luchinat, C., Bertini, I., & Galli, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.050 · Cited by 11
Nava, M. B., Catanuto, G. F., Pennati, A., Rocco, N., Spanò, A., Villa, R., & Daidone, M. G. (2015) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000001008 · Cited by 11
DNA-RNA hybrid G-quadruplex tends to form near the 3′ end of telomere overhang
Choi, B.-E., & Lee, H.-T. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.06.026 · Cited by 11
Ajaykumar, A., Caloren, L. C., Povshedna, T., Hsieh, A. Y. Y., Zakaria, A., Cai, R., Smith, M.-S. R., Thompson, C. A. H., Becquart, P., Uday, P., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003369 · Cited by 11
Khleifat, A. A., Iacoangeli, A., Jones, A. R., van Vugt, J. J. F. A., Moisse, M., Shatunov, A., Zwamborn, R. A. J., van der Spek, R. A. A., Cooper‐Knock, J., Topp, S. D., et al. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1050596 · Cited by 13
“While telomere shortening is typically seen in cancers, telomere elongation can occur in cancers of the nervous system, and for example, is seen in 25% of primary brain tumors, in glioblastoma multiforme and in 10% of neuroblastomas (Bryan et al., 1997; Hakin-Smith et al., 2003; Henson et al., 2005; Durant, 2012; Bout…”
BackgroundYoshikawa, H., Maranon, D. G., Battaglia, C. L. R., Ehrhart, E. J., Charles, J. B., Bailey, S. M., & LaRue, S. Μ. (2014) · Veterinary and Comparative Oncology · doi:10.1111/vco.12117 · Cited by 14
Telomere Recombination Preferentially Occurs at Short Telomeres in Telomerase-Null Type II Survivors
Fu, X.-H., Duan, Y., Liu, Y., Cai, C., Meng, F., & Zhou, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090644 · Cited by 13
Mersaoui, S. Y., Gravel, S., Karpov, V., & Wellinger, R. J. (2015) · Microbial Cell · doi:10.15698/mic2015.10.229 · Cited by 13
“It has been speculated that particularly type II survivor yeast cells resemble human cancerous cells that replenish their telomeric repeat DNA via alternative telomeraseindependent mechanisms (alternative lengthening of telomeres, or ALT), [30, 31].”
BackgroundMechanisms of Gastrointestinal Malignancies
Katona, B. W., & Lynch, J. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00066-9 · Cited by 13
Telomere Length in Metaphase Chromosomes of Human Triploid Zygotes
Pendina, A. A., Krapivin, M. I., Efimova, O. A., Tikhonov, A. V., Дмитриевна, М. И., Komarova, E. M., Koltsova, A. S., Gzgzyan, A. M., Kogan, I. Y., Chiryaeva, O. G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115579 · Cited by 11
“On the other hand, they can lengthen due to telomerase reverse transcriptase activity [19] and through a recombination-based mechanism termed alternative lengthening of telomeres (ALT) [20,21].”
BackgroundhTERT immunopositivity patterns in the normal brain and in astrocytic tumors
Kotoula, V., Cheva, A., Barbanis, S., Papadimitriou, C. S., & Karkavelas, G. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0036-1 · Cited by 11
“About 34% of astrocytomas use the ALT mechanism that is found more frequently in low-grade tumors [13], while absence of hTERT expression in glioblastomas employing the ALT mechanism with long telomeres is associated with a better prognosis [11, 13].”
BackgroundThe Detection and Analysis of Chromosome Fragile Sites
Bjerregaard, V. A., Özer, Ö., Hickson, I. D., & Liu, Y. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7306-4_31 · Cited by 11
Bejarano, L., Louzame, J., Montero, J. J., Megías, D., Flores, J. M., & Blasco, M. A. (2019) · iScience · doi:10.1016/j.isci.2019.08.012 · Cited by 11
“Telomeres can also be elongated by an alternative mechanism known as alternative lengthening of telomeres (ALT), which is based on homologous recombination (Bryan et al., 1997).”
BackgroundInfluentialTelomerase in Cancer Diagnosis and Therapy
Burger, A. M. (1999) · BioDrugs · doi:10.2165/00063030-199912060-00001 · Cited by 11
“Moreover, tumour cells under high selection pressure could switch to telomerase-independent pathways for maintenance of telomere length, such asALT (alternative lengthening of telomeres).[55] The occurrence of ALT is used to explain the phenomenon seen in some 25% of in vitro immortalised cell lines which have no dete…”
BackgroundTelomerase inhibitors: a new option for chemotherapy
Chen, Z., & Corey, D. R. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)87173-7 · Cited by 15
Telomerase inhibitors: a new option for chemotherapy
Chen, Z. J., & Corey, D. R. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)87294-9 · Cited by 11
Telomere length and telomerase activity in the process of human fibroblast immortalization
Kumakura, S., Yamamoto, A., Yagisawa, J., Uchida, M., & Tsutsui, T. W. (2002) · Odontology · doi:10.1007/s102660200002 · Cited by 11
Telomere stability genes are not mutated in osteosarcoma cell lines
Savage, S. A., Stewart, B., Liao, J. S., Helman, L. J., & Chanock, S. J. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.12.004 · Cited by 12
Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity
Machitani, M., Nomura, A., Yamashita, T., Yasukawa, M., Ueki, S., Fujita, K.-I., Ueno, T., Yamashita, A., Tanzawa, Y., Watanabe, M., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01427-6 · Cited by 10
“The authors revealed that these ALT cells completely lack telomerase activity 23 and that the ALT mechanism occurs in human tumours 24 .”
Pirota, V., Iachettini, S., Platella, C., Zizza, P., Fracchioni, G., Vito, S. D., Carachino, A., Battistini, F., Orozco, M., Freccero, M., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf301 · Cited by 10
Zhang, Y., Luo, S., Jia, Y., & Zhang, X. (2022) · International Journal of Cancer · doi:10.1002/ijc.34007 · Cited by 10
“The detailed data inclusion criteria were depicted in Figure S1.”
MethodInfluentialRaseley, K., Jinwala, Z., Zhang, D., & Xiao, M. (2023) · Genes · doi:10.3390/genes14061278 · Cited by 11
“Here, we reported shorter overall mean telomere lengths in ALT+ cell lines, specifically U2OS, compared to previously published studies [26,27].”
BackgroundResultALTercations at telomeres: stress, recombination and extrachromosomal affairs
Loe, T. K., Denchi, E. L., Tricola, G. M., & Azeroglu, B. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230265 · Cited by 12
Tlemsani, C., Heske, C. M., Elloumi, F., Pongor, L. S., Khandagale, P., Varma, S., Luna, A., Meltzer, P. S., Khan, J. I., Reinhold, W. C., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109781 · Cited by 12
Fukushima, T., Yoshino, A., Katayama, Y., Watanabe, T., Kusama, K., & Moro, I. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00357-9 · Cited by 10
Potential clinical role of telomere length in human glioblastoma.
Torre, D. L., Aguennouz, M., Conti, A., Giusa, M., Raffa, G., Abbritti, R. V., Germanò, A., & Angileri, F. F. (2011) · Europe PMC (PubMed Central) · Cited by 13
Puthumana, J., Sukumaran, V., Priyaja, P., Philip, R., & Singh, I. S. B. (2015) · Cytotechnology · doi:10.1007/s10616-015-9890-9 · Cited by 10
“Besides, the telomerase-independent mechanism of telomere maintenance, such as the alternative lengthening of telomeres (ALT) has been reported in Drosophila (Pardue et al. 1996), yeasts (Lundblad and Blackburn 1993) and human (Bryan et al. 1995, 1997; Henson et al. 2002).”
Multiple Mechanisms Contribute To Telomere Maintenance.
Morrish, T. A., Bekbolysnov, D., Velliquette, D., Morgan, M., Ross, B., Wang, Y., Chaney, B., McQuigg, J. L., Fager, N., & Maine, I. P. (2013) · PubMed · Cited by 13
Dynamic Length Changes of Telomeres and Their Nuclear Organization in Chronic Myeloid Leukemia
Samassékou, O. (2013) · Cancers · doi:10.3390/cancers5031086 · Cited by 13
“ALT is the other telomere length maintenance mechanism, present in 15% of tumors [13,14].”
BackgroundAsaad, N. Y., El‐Wahed, M. M. A., & Ag, M. (2006) · PubMed · Cited by 10
Guarding chromosomes from oxidative DNA damage to the very end
Tan, R., & Lan, L. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw040 · Cited by 10
“About 10%–15% cancer cells acquire the ALT mechanism to support the infinite proliferation and survival [30].”
Jamiruddin, M. R., Kaitsuka, T., Hakim, F., Fujimura, A., Wei, F., Saitoh, H., & Tomizawa, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.026 · Cited by 10
Telomerase Activity in Sex Cord–Stromal Tumors of the Ovary
Dowdy, S. C., O’Kane, D. J., Keeney, G. L., Boyd, J. A., & Podratz, K. C. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6293 · Cited by 10
“This suggests that a larger proportion f these tumors may overcome telomere shortening through a athway called alternative lengthening of telomeres [11, 12].”
BackgroundLee, H.-W., Roh, J.-I., & Sung, Y. H. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50918 · Cited by 10
“telomerase-negative cancer cells that maintain their telomeres through alternative lengthening of telomere.(28,29) As the folding of a telomere to G-quadruplex (G4) prevents telomerase-induced telomere elongation,(30,31) ligands that induce and stabilize G4 structures can be used as effective drugs against telomerase-…”
Molekularmedizinische Grundlagen von altersspezifischen Erkrankungen
Ganten, D., & Bähr, M. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4 · Cited by 11
Duncan, E. L., Perrem, K., & Reddel, R. R. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3501 · Cited by 10
Self-citationTelomere length in familial adenomatous polyposis-associated desmoids
Middleton, S. B., Pack, K., & Phillips, R. K. S. (2000) · Diseases of the Colon & Rectum · doi:10.1007/bf02236734 · Cited by 11
The Cancer–Aging Interface and the Significance of Telomere Dynamics in Cancer Therapy
Tallen, G. R. N., Soliman, M. A., & Riabowol, K. T. (2007) · Rejuvenation Research · doi:10.1089/rej.2007.0598 · Cited by 12
“24 In most human primary cells, telomerase activity is not detected or is insufficient to maintain telomere length.”
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.